uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
27.51
-0.12 (-0.43%)
At close: Nov 28, 2025, 1:00 PM EST
27.50
-0.01 (-0.04%)
After-hours: Nov 28, 2025, 4:51 PM EST
uniQure Revenue
uniQure had revenue of $3.70M in the quarter ending September 30, 2025, with 61.83% growth. This brings the company's revenue in the last twelve months to $15.75M, down -44.90% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$15.75M
Revenue Growth
-44.90%
P/S Ratio
94.54
Revenue / Employee
$75,364
Employees
209
Market Cap
1.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
QURE News
- 12 days ago - Diamond Hill International Strategy Q3 2025 Performance Review - Seeking Alpha
- 16 days ago - uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE - PRNewsWire
- 17 days ago - QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 19 days ago - From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside - Seeking Alpha
- 19 days ago - uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 23 days ago - uniQure to Announce Third Quarter 2025 Financial Results - GlobeNewsWire
- 26 days ago - UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data - Benzinga